← Leaderboards
Michael Levy
Massachusetts General Hospital
$4,359,862
Attributed
$4,507,387
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $691.3K · FY2013–25$1M$750K$500K$250K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,507,387 · 4
By mechanism
R01$3,247,221 · 2
K08$965,115 · 1
R43$295,051 · 1
Top collaborators
- Joseph J Catino1 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- David Nelson Kennedy$22,953,236
- Joren C Madsen$70,026,219
- Robert McCullough Anthony$13,511,733
- Dimitri Krainc$24,610,296
- Caterina Mainero$3,830,889
Others in their field
Top investigators on “Immune”
- Lawrence Corey · Fred Hutchinson Cancer Center$680,290,567
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$541,067,641
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$470,748,611
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
- Judith S. Currier · University Of California Los Angeles$334,425,492
Research focus
ImmuneMediatingCellsSpinal CordParalysedInsightTransverse MyelitisPathogenesisBiological MarkersInflammatoryNeuraxisExperimental Autoimmune EncephalomyelitisPathogenicityPeptidesMultiple SclerosisImmune ResponseAntigensImmune SystemNeuromyelitis OpticaInflammationAntibodiesAnimal ModelAstrocytesAquaporin 4
Grant awards (14)
The Immunopathogenesis of Familial Transverse Myelitis Due to Mutations in VPS37a$404,975
R01 · FY2025 · AI · contact PI
The Immunopathogenesis of Familial Transverse Myelitis Due to Mutations in VPS37a$417,500
R01 · FY2024 · AI · contact PI
The Immunopathogenesis of Familial Transverse Myelitis Due to Mutations in VPS37a$417,500
R01 · FY2023 · AI · contact PI
Developing Tolerization Therapies from a New T-cell Based Mouse Model of Neuromyelitis Optica$396,200
R01 · FY2022 · AI · contact PI
Developing Tolerization Therapies from a New T-cell Based Mouse Model of Neuromyelitis Optica$396,200
R01 · FY2021 · AI · contact PI
Spatiotemporal tuning of myelin antigens and rapamycin for enhanced antigen-specific immune tolerance in multiple sclerosis.$295,051
R43 · FY2021 · AI
Developing Tolerization Therapies from a New T-cell Based Mouse Model of Neuromyelitis Optica$396,200
R01 · FY2020 · AI · contact PI
Developing Tolerization Therapies from a New T-cell Based Mouse Model of Neuromyelitis Optica$409,375
R01 · FY2019 · AI · contact PI
Developing Tolerization Therapies from a New T-cell Based Mouse Model of Neuromyelitis Optica$409,271
R01 · FY2018 · AI · contact PI
immunopathogenesis of NMO-IgG and AQP4-specific T cells in neuromyelitis optica$193,023
K08 · FY2017 · NS · contact PI
immunopathogenesis of NMO-IgG and AQP4-specific T cells in neuromyelitis optica$193,023
K08 · FY2016 · NS · contact PI
immunopathogenesis of NMO-IgG and AQP4-specific T cells in neuromyelitis optica$193,023
K08 · FY2015 · NS · contact PI
immunopathogenesis of NMO-IgG and AQP4-specific T cells in neuromyelitis optica$193,023
K08 · FY2014 · NS · contact PI
immunopathogenesis of NMO-IgG and AQP4-specific T cells in neuromyelitis optica$193,023
K08 · FY2013 · NS · contact PI